Chitosan/β-glycerophosphate in situ gelling mucoadhesive systems for intravesical delivery of mitomycin-C

in situ gelling systems for drug delivery

In Situ Gelling Systems for Drug Delivery

Implication for health policy/practice/research/medical education: Development of polymeric in situ gels for controlled release of various drugs provides a number of advantages over conventional dosage forms. Some important advantages of these smart systems are ease of application and reduced frequency of administration, as well as protection of the drug from environmental conditions. Published...

Ion-activated In Situ Gelling Ophthalmic Delivery Systems of Azithromycin

Gelation of pectin caused by divalent cations especially calcium ions has been applied to develop an ophthalmic formulation of azithromycin in the present study. Rapid elimination of drug on instillation into cul de sac would be minimal with in situ gelling ophthalmic solution leading to increased precorneal contact time and prolonged drug delivery. In the formulation development studies pectin...

Therapies in bladder cancer: intravesical mitomycin-C

The use of intravesical therapy for the treatment of superficial bladder cancer aims to reduce morbidity and mortality by eradicating existing disease, preventing tumor recurrence and attempting to halt tumor progression. Mitomycin-C is a commonly used intravesical treatment option for superficial bladder cancer and was used for the first time by Shida and colleagues in 1967 [1]. It is an antit...

Intravesical mitomycin-C-induced interstitial pneumonia.

An 84-year-old man with no evidence of pre-existing interstitial pneumonia developed fatal interstitial pneumonia and respiratory failure that could only be explained as an adverse effect of intravesical mitomycin C chemotherapy. He had undergone transurethral resection of bladder cancer 3 times, followed by intravesical mitomycin C chemotherapy 1 month later. He had received intravesical mitom...